Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
GlobeNewswire
Substantial reductions seen in lyso-Gb1, an established biomarker of clinical response, in patients with persistently high levels..